← Leaderboards
David C. Kaslow
Vical, Inc.
$2,089,603
Attributed
$2,089,603
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2005–06$2M$1.5M$1M$500K$0
'05
'06
Funding mix
By agency
NIH$2,089,603 · 1
By mechanism
R44$2,089,603 · 1
Top collaborators
No co-investigators on record.
Most similar at Vical, Inc.
Same institution · by research overlap
- Peggy Lalor$3,895,660
- Peter M. Hobart$2,818,910
- Mary K Wloch$258,937
- Ronald B Moss$1,047,535
- Sean M. Sullivan$1,999,533
Others in their field
Top investigators on “Clinical Trial Phase I”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$674,722,986
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$549,289,302
- Barton F Haynes · Duke University$532,133,792
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$407,280,377
Research focus
Clinical Trial Phase IClinical Trial Phase IiHerpesviridae Vaccine